Alfasigma pays $300 million for rights to GSK's rare liver disease drug, awaits FDA decision

GSK has granted Alfasigma global rights to Linerixibat, a treatment for the rare liver disease primary biliary cholangitis (PBC). This follows Alfasigma's voluntary withdrawal in 2025 from the market of Ocaliva, a PBC drug that has triggered safety concerns from U.S. and European regulators.

The post Alfasigma Pays $300 Million for Rights to GSK’s Rare Liver Disease Drug Awaiting FDA Decision appeared first on MedCity News.